ImetelChat

Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes MENLO PARK, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in pat...

Great article from Hoosier (SA, 12 January 2016). Herewith some parts of it. Summary - Second-line myelofibrosis represents a $1.1B net sales opportunity. - Low & Int-1 risk MDS represents a $3.7B net sales opportunity. - AML, multiple myeloma, and solid tumors are future opportunities. - A forthcom...

Bio, thanks for your interesting post. I think it is realistic that BAT is around the corner. We only know it when we see it. But taking the anticipated approval of 2017 seriously, would mean that a very fast process towards approval is needed. btw: here is the link: http://www.brookings.edu/events/...

Here is a link to the presentation of Dr.Scarlet today at the J.P. Morgan Healthcare Conference: http://www.sec.gov/Archives/edgar/data/886744/000120677416004051/exhibit99-1.htm and a link to the full archive of todays Geron SEC K-8 Form filing: http://www.sec.gov/Archives/edgar/data/886744/00012067...

Bio, agree, long way to go. But there are more potential events that can trigger PPS, such as positive results about efficacy and safety as soon as the Part 1 IMerge read-outs. And not to forget potential fast track... btw: this is the link to the timeline slide: http://www.sec.gov/Archives/edgar/da...

From K8 filing today (11 January 2016): Geron Corporation (the “Company” or “Geron”) will be providing financial information about the Company’s cash and investment balances as of December 31, 2015 in the Company’s presentation handout to be utilized in various meetings with securities analysts and ...

by irishtrader52, from YMB (11 Januari 2016) John at Mayo last week. General "talk" at water cooler good. John health and blood counts very, very good. Same old great news on that account. Did not see Dr. Tefferi or Dr. Gagnat this time. Both very busy and Dr. T. traveling. We expect a very happy ne...

Hi bio, thanks for signalling. I will copy her post from YMB into here.

Hi Bio, I agree that the title suggests more about PV. I guess there must be some tactics behind that. My take is that imet will be used off label for other MPN's as soon it is approved for MF or MDS (which one will be first?). ET and PV are dangerous diseases indeed which in the end better get 'cur...

Hi Generous, thanks for joining! Things in early biotech go slow for a long time, and when proven succesful things can change very quickly. For over a year now we have only good news and confirmations that imetelstat is safe and effective. The shorting of GERN is immense. Good news (e.g. fast track,...

The transaction date is 31 Dec 2015. She now owns 35,109 shares of Geron. Explanation from the SEC Form 4, filed on 01/04/2016: Shares issued in lieu of cash payment for quarterly board of directors retainer fee. Number of shares issued based on close price on December 31, 2015 of $4.84 per share. L...

Hi Bio, releasing information has to meet at least two criteria: 1) it needs to be accurate and well prepared and 2) it needs to be relevant for their business. Releasing information about the PV patients doesn't serve any objectives, as PV is not on the list of pursued indications. Releasing inform...

Some time ago I found out that an old friend of mine had become a principle hematologist at an academic hospital. He has many years of experience with MPN patients, including MDS, AML and all other myeloid malignancies. I asked him about imetelstat. His first response was: "a beautiful drug". He att...

Happy new year all of you! Let's see what developments we will see this year. I expect it to be rather dynamic: early read outs, fast track, JNJ continuation decision, next milestone payment, AML start, new indications..... Geron just filed two new patents: 1 20150374841 12/31/15 Oligonucleotide con...

Myelosuppression seems to be a returning discussion point, mostly in the context of an adverse side effect or toxicity. After the ASH investors meeting on 6 December, sdrawkcabeman, the best poster on YMB, commented the following: "Everyone on that panel acknowledges all toxicities are predictably a...

On YMB mangymutt stated that Scarlet bought 50,000 shares at $1.03 on 04/01/2013. I don't know where that price came from, maybe from earlier options or some special reserved stock (the pps was higher at that time, around $1.40). Because part of his salary is paid in options, he will have various bl...

I believe it was in the 5's, but I don't have a good source for that.

Gimp, just take another look at my earlier posts regarding the continuation decision and milestone payments (both 17 Dec). There you should be able to find some rationale for your speculation. Would be interesting to elaborate on that.

Thanks for posting to this board. There is a lot to speculate about. Could you substantiate your speculation? Otherwise we will soon be overloaded here with with dozens of other potential speculations out of thin air.

This list provides an overview of the latest patents filed by Geron in 2015. 1 20150359883 12/17/15 Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors 2 20150342982 12/03/15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproli...